← Leaderboards
Steven R Alberts
Mayo Clinic
$13,460,245
Attributed
$19,282,332
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–23$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$19,282,332 · 11
By mechanism
U10$6,623,069 · 1
P30$5,379,313 · 6
UG1$5,021,105 · 1
P50$2,257,918 · 2
M01$927 · 1
Top collaborators
- Judy Caroline Boughey11 shared
Others in their field
Top investigators on “Grant”
- David R. Weir · University Of Michigan At Ann Arbor$373,949,788
- David Heimbrook · Leidos Biomedical Research, Inc.$341,196,902
- Eric S Lander · Whitehead Institute For Biomedical Res$323,181,457
- Jeffrey P Krischer · University Of South Florida$258,583,867
- Lawrence Corey · Fred Hutchinson Cancer Center$253,286,867
- Barton F Haynes · Duke University$243,251,908
Research focus
GrantClinical ResearchResearch PersonnelMayo Clinic Cancer CenterFundingEnsureProgramsMalignant NeoplasmsClinical TrialsLeadResourcesParticipantReportingComprehensive Cancer CenterBaseFutureClinicNorth Central Cancer Treatment GroupArizonaStructureMonitorFloridaCancer Center Support GrantDatabases
Grant awards (47)
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1$867,908
UG1 · FY2023 · CA · contact PI
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1$931,004
UG1 · FY2022 · CA · contact PI
Project 3: Inhibition of SCD1 as a therapeutic strategy for HCC$358,289
P50 · FY2022 · CA · contact PI
Core C: Biospecimen and Pathology Core$278,121
P50 · FY2022 · CA · contact PI
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1$1,084,135
UG1 · FY2021 · CA · contact PI
Core C: Biospecimen and Pathology Core$327,870
P50 · FY2021 · CA · contact PI
Project 3: Inhibition of SCD1 as a therapeutic strategy for HCC$314,522
P50 · FY2021 · CA · contact PI
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1$984,029
UG1 · FY2020 · CA · contact PI
Project 3: Inhibition of SCD1 as a therapeutic strategy for HCC$331,658
P50 · FY2020 · CA · contact PI
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1$170,000
UG1 · FY2020 · CA · contact PI
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1$984,029
UG1 · FY2019 · CA · contact PI
Project 3: Inhibition of SCD1 as a therapeutic strategy for HCC$307,550
P50 · FY2019 · CA · contact PI
Project 3: Inhibition of SCD1 as a therapeutic strategy for HCC$12,136
P50 · FY2019 · CA · contact PI
Project 3: Inhibition of SCD1 as a therapeutic strategy for HCC$12,136
P50 · FY2019 · CA · contact PI
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site$1,223,634
U10 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$343,268
P30 · FY2018 · CA · contact PI
Project 3: Inhibition of SCD1 as a therapeutic strategy for HCC$315,636
P50 · FY2018 · CA · contact PI
Early Phase Clinical Research Support$204,008
P30 · FY2018 · CA · contact PI
Early Phase Clinical Research Support$7,438
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$7,438
P30 · FY2018 · CA · contact PI
Early Phase Clinical Research Support$6,546
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$6,546
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$2,609
P30 · FY2018 · CA · contact PI
Early Phase Clinical Research Support$2,609
P30 · FY2018 · CA · contact PI
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site$1,367,856
U10 · FY2017 · CA · contact PI
Clinical Protocol and Data Management$346,845
P30 · FY2017 · CA · contact PI
Early Phase Clinical Research Support$206,137
P30 · FY2017 · CA · contact PI
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site$1,295,865
U10 · FY2016 · CA · contact PI
Clinical Protocol and Data Management$343,268
P30 · FY2016 · CA · contact PI
Early Phase Clinical Research Support$204,011
P30 · FY2016 · CA · contact PI
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site$1,295,864
U10 · FY2015 · CA · contact PI
Clinical Protocol and Data Management$343,209
P30 · FY2015 · CA · contact PI
Early Phase Clinical Research Support$204,952
P30 · FY2015 · CA · contact PI
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site$1,439,850
U10 · FY2014 · CA · contact PI
Clinical Protocol and Data Management$327,039
P30 · FY2014 · CA · contact PI
Early Phase Clinical Research Support$199,078
P30 · FY2014 · CA · contact PI
Clinical Research$437,135
P30 · FY2013 · CA · contact PI
Clinical Research$375,852
P30 · FY2012 · CA · contact PI
Clinical Research$450,435
P30 · FY2011 · CA · contact PI
Clinical Research$476,628
P30 · FY2010 · CA · contact PI
Clinical Research$471,023
P30 · FY2009 · CA · contact PI
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$112,283
P30 · FY2008 · CA · contact PI
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$112,301
P30 · FY2007 · CA · contact PI
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$61,578
P30 · FY2006 · CA · contact PI
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$60,674
P30 · FY2005 · CA
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$66,403
P30 · FY2004 · CA
Phase II Trial of Gemcitabine and Docetaxel$927
M01 · FY2004 · RR